摘要
目的对比研究氯吡格雷和替格瑞洛治疗急性ST段抬高型心肌梗死(STEMI)患者的疗效。方法选取2022年3月至2024年11月在新乡市第二人民医院治疗的60例STEMI患者,按照随机数字法分为A组及B组,A组患者术前及术后给予阿司匹林肠溶片及硫酸氢氯吡格雷片治疗,B组术前及术后给予阿司匹林肠溶片及替格瑞洛片治疗,比较两组疗效。结果治疗前,两组氨基末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)水平比较,差异无统计学意义(P>0.05);治疗6个月后,B组NT-proBNP及LVEDD水平显著低于A组,LVEF显著高于A组,差异有统计学意义(P<0.05)。两组非致死性心肌梗死、非致死性脑卒中、急性心力衰竭及全因死亡发生率比较,差异无统计学意义(P>0.05)。两组恶心呕吐、胃肠道出血、呼吸困难、肝功能损伤、肾功能损伤发生率比较,差异无统计学意义(P>0.05)。结论替格瑞洛联合阿司匹林肠溶片治疗STEMI患者相较于氯吡格雷联合阿司匹林肠溶片改善心肌损伤与心功能较为明显,且不会额外增加不良事件风险。
Objective To compare the efficacy of clopidogrel and ticagrelor in the treatment of patients with acute STsegment elevation myocardial infarction(STEMI).Methods A total of 60 patients with STEMI who were treated at the Second People’s Hospital of Xinxiang from March 2022 to November 2024 were selected and randomly divided into group A and group B by a random number method.Patients in group A received enteric-coated aspirin tablets combined with clopidogrel hydrogen sulfate tablets before and after the procedure,whereas patients in group B received enteric-coated aspirin tablets combined with ticagrelor tablets before and after the procedure.The therapeutic efficacy was compared between the two groups.Results Before treatment,there were no statistically significant differences between the two groups in N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF),or left ventricular end-diastolic diameter(LVEDD)(P>0.05).After 6 months of treatment,NT-proBNP,and LVEDD levels in group B were significantly lower than those in group A,while LVEF was significantly higher than that in group A(P<0.05).There were no statistically significant differences between the two groups in the incidences of non-fatal myocardial infarction,non-fatal stroke,acute heart failure,or all-cause mortality(P>0.05).The incidences of nausea and vomiting,gastrointestinal bleeding,dyspnea,liver function impairment,and renal function impairment also did not differ significantly between the two groups(P>0.05).Conclusion Compared with clopidogrel combined with enteric-coated aspirin,ticagrelor combined with enteric-coated aspirin provides more pronounced improvement in myocardial injury and cardiac function in patients with STEMI,without increasing the risk of adverse events.
作者
寇广亚
梁伟
KOU Guangya;LIANG Wei(Department of Cardiology,Second People’s Hospital of Xinxiang,Xinxiang 453000,Henan,China)
出处
《临床研究》
2025年第12期92-95,共4页
Clinical Research
